NADPH oxidase (NOX) isoforms are inhibited by celastrol with a dual mode of action
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND Celastrol is one of several bioactive compounds extracted from the medicinal plant Tripterygium wilfordii. Celastrol is used to treat inflammatory conditions, and shows benefits in models of neurodegenerative disease, cancer and arthritis, although its mechanism of action is incompletely understood. EXPERIMENTAL APPROACH Celastrol was tested on human NADPH oxidases (NOXs) using a panel of experiments: production of reactive oxygen species and oxygen consumption by NOX enzymes, xanthine oxidase activity, cell toxicity, phagocyte oxidase subunit translocation, and binding to cytosolic subunits of NOX enzymes. The effect of celastrol was compared with diphenyleneiodonium, an established inhibitor of flavoproteins. KEY RESULTS Low concentrations of celastrol completely inhibited NOX1, NOX2, NOX4 and NOX5 within minutes with concentration–response curves exhibiting higher Hill coefficients and lower IC 50 values for NOX1 and NOX2 compared with NOX4 and NOX5, suggesting differences in their mode of action. In a cell‐free system, celastrol had an IC 50 of 1.24 and 8.4 µM for NOX2 and NOX5, respectively. Cytotoxicity, oxidant scavenging, and inhibition of p47 phox translocation could not account for NOX inhibition. Celastrol bound to a recombinant p47 phox and disrupted the binding of the proline rich region of p22 phox to the tandem SH3 domain of p47 phox and NOXO1, the cytosolic subunits of NOX2 and NOX1, respectively. CONCLUSIONS AND IMPLICATIONS These results demonstrate that celastrol is a potent inhibitor of NOX enzymes in general with increased potency against NOX1 and NOX2. Furthermore, inhibition of NOX1 and NOX2 was mediated via a novel mode of action, namely inhibition of a functional association between cytosolic subunits and the membrane flavocytochrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989
Self-citationNOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation
Serrander, L., Cartier, L., Bedard, K., Banfi, B., Lardy, B., Plastre, O., Sienkiewicz, A., Fórró, L., Schlegel, W., & Krause, K.-H. (2007) · Biochemical Journal · doi:10.1042/bj20061903 · Cited by 627
Self-citationResidual NADPH Oxidase and Survival in Chronic Granulomatous Disease
Kuhns, D. B., Alvord, W. G., Heller, T., Feld, J. J., Pike, K. M., Marciano, B. E., Uzel, G., DeRavin, S. S., Priel, D. A. L., Soule, B. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007097 · Cited by 568 · cited 2×
“…mutation with very low NOX2 expression are generally healthy (Kume and Dinauer, 2000) and patients who retain some residual production of ROS have a less severe disease (Kuhns et al., 2010), suggesting that decreases in NOX2 activity do not necessarily lead to a complete loss of immune function.”
BackgroundAllison, A. C., Cacabelos, R., Lombardi, V. R. M., Álvarez, X. A., & Vigo, C. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00192-0 · Cited by 376 · cited 2×
“Celastrol has a rather broad range of actions attributed to it, including inhibition of NF-kB, ERK, TNF-a, IL-1, and NO (Allison et al., 2001; Kim et al., 2009), inhibition of heatshock protein 90 (Zhang et al.”
BackgroundMolecular basis for Rac2 regulation of phagocyte NADPH oxidase
Diebold, B. A., & Bokoch, G. M. (2001) · Nature Immunology · doi:10.1038/85259 · Cited by 318 · cited 1×
“For NOX2, a semi-recombinant system was used as previously described with the modification that MCLA (10 mM) was used instead of L-012 (Diebold and Bokoch, 2001).”
MethodNox enzymes as novel targets for drug development
Lambeth, J. D., Krause, K.-H., & Clark, R. A. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0123-6 · Cited by 212 · cited 1×
“The role of NOX enzymes in oxidative stress-related pathologies is increasingly recognized, in particular for cardiovascular and neurodegenerative diseases, and they represent a promising pharmacological target (Lambeth et al., 2008).”
BackgroundSelf-citationSERRANDER, L., JAQUET, V, BEDARD, K., PLASTRE, O., HARTLEY, O., ARNAUDEAU, S., DEMAUREX, N., SCHLEGEL, W., & KRAUSE, K. (2007) · Biochimie · doi:10.1016/j.biochi.2007.05.004 · Cited by 146 · cited 3×
“…of PMA (0.1 mM); (iii) an HEK293T NOX4 inducible cell line that, upon addition of tetracycline, expresses NOX4 and produces ROS spontaneously (Serrander et al., 2007a); and (iv) an HEK cell line stably expressing NOX5 that produces ROS in response to Ca2+ influx induced by the ionophore…”
BackgroundMethodInfluentialSelf-citation
Cited by
Kirkham, P. A., & Barnes, P. J. (2013) · Chest · doi:10.1378/chest.12-2664 · Cited by 685
Nox family NADPH oxidases: Molecular mechanisms of activation
Brandes, R. P., Weissmann, N., & Schröder, K. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.07.046 · Cited by 673
Evolution of nadph oxidase inhibitors: Selectivity and mechanisms for target engagement
Altenhöfer, S., Radermacher, K. A., Kleikers, P. W. M., Wingler, K., & Schmidt, H. H. H. W. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5814 · Cited by 521
NADPH Oxidases in Vascular Pathology
Konior, A., Schramm, A., Czesnikiewicz-Guzik, M., & Guzik, T. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5607 · Cited by 452
The NOX toolbox: validating the role of NADPH oxidases in physiology and disease
Altenhöfer, S., Kleikers, P. W. M., Radermacher, K. A., Scheurer, P., Rob Hermans, J. J., Schiffers, P., Ho, H., Wingler, K., & Schmidt, H. H. H. W. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1010-9 · Cited by 371
Metadata
- Authors
- Jaquet, V., Marcoux, J., Forest, E., Leidal, K. G., McCormick, S., Westermaier, Y., Perozzo, R., Plastre, O., Fioraso‐Cartier, L., Diebold, B., Scapozza, L., Nauseef, W. M., Fieschi, F., Krause, K., & Bedard, K.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-08-28
- Volume
- 164
- Issue
- 2b
- Pages
- 507-520
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1560738700
- Cited by
- 119
- References
- 7
- FWCI
- 18.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NADPH oxidase (NOX) isoforms are inhibited by celastrol with a dual mode of action. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01439.x
- The paper
- Jaquet, V., Marcoux, J., Forest, E., Leidal, K. G., McCormick, S., Westermaier, Y., Perozzo, R., Plastre, O., Fioraso‐Cartier, L., Diebold, B., Scapozza, L., Nauseef, W. M., Fieschi, F., Krause, K., & Bedard, K. (2011). NADPH oxidase (NOX) isoforms are inhibited by celastrol with a dual mode of action. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01439.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.